CURRICULUM VITAE
`
`Scott Avard MacDia1'rnid, MD, FRCPSC
`
`Alliance Urology Specialists
`509 N Elam Ave., 2"“ Floor
`Greensboro. NC 27403
`
`Telephone: 336 274 1114
`Email: s1nacdia11nid@a1lianceurology.com
`
`PERSONAL INFORMATION:
`
`Birthplace and Date:
`
`Moncton, New Brunswick, Canada
`November 27, 1960
`
`Citizenship:
`
`Canada and United States (2006)
`
`Marital Status:
`
`Spouse’s Name:
`
`Children:
`
`EDUCATION:
`
`Married
`
`Andrea
`
`Lindsey
`
`1981
`
`1985
`
`Dalhousie University
`Halifax, Nova Scotia, Canada
`B.S.
`
`Dalhousie University
`Halifax, Nova Scotia, Canada
`M.D.
`
`POSTDOCTURAL
`
`Internship:
`
`1985-86
`
`Residency:
`
`1987-91
`
`Fellowships:
`
`1991-1992
`
`Rotating
`Dalhousie University
`Halifax, Nova Scotia, Canada
`
`Urology
`Dalhousie University
`Halifax, Nova Scotia, Canada
`
`Reconstructive Urology and Urodynamics
`Duke University Medical Center
`Durham, North Carolina
`
`Patent Owner, UCB Pharma GmbH — Exhibit 2060 - 0001
`
`

`
`MacDiarmid, Scott A., M.D.
`Curriculum Vitae
`
`Page 2 of 50
`
`Fellowships continued
`
`I993
`
`I993
`
`PROFESSIONAL LICENSURE:
`
`SPECIALTY CERTIFICATION:
`
`Reconstructive Urology and Urodynarnics
`University of Otago
`Christchurch, New Zealand (9 months)
`
`Neuro-Urology, Reconstructive Urology
`Lodgemoor Spinal Unit, University of Sheffield
`Sheffield, England (4 months)
`
`North Carolina Medical License # 2003-00648
`
`September, 1991
`
`Fellow, Royal College of Physicians and Surgeons of Canada
`
`February, l996
`
`The American Board of Urology # 1 1273
`Rcccrtificd: November, 2004
`
`Recertified: August, 2013
`
`August, 2013
`
`Subspecialty certification: Female Pelvic Medicine and
`Reconstructive Surgery (PPM-RS)
`
`EMPLOYMENT:
`
`Academic/Professional Appointments:
`
`2015—Prcsent
`
`Clinical Associate Professor
`
`Department of Urology
`The University of North Carolina
`Chapel Hill, NC
`
`2006—Presscnt
`
`Director Bladder Control and Pelvic Pain Center
`
`2003—July 06
`
`Alliance Urology Specialists
`Greensboro, NC
`
`Associate Professor of Surgery (Urology)
`Department of Urology
`Wake Forest University School of Medicine
`Winston—Salem, NC
`
`Head
`
`Reconstructive Urology and Urodynamics
`
`Patent Owner, UCB Pharma GmbH — Exhibit 2060 - 0002
`
`

`
`Director
`
`MacDiarmid, Scott A., M.D.
`Curriculum Vitae
`
`Page 3 of 50
`
`Wake Forest University Continence Center
`
`l999—2003
`
`Associate Professor
`
`Department of Urology
`University of Tennessee
`Memphis, TN
`
`Head
`
`Section of Urodynamics and Neuro—urology
`
`Director
`UT Bladder Control and Pelvic Pain Center
`
`Service Chief
`
`Methodist University Hospital
`
`Faculty Urologist
`UT Medical Group
`Department of Urology
`
`Deputy Research Director and Primary Investigator
`Raines—Cox Urology Institute
`Memphis, TN
`
`1994-1999
`
`Associate Professor
`
`Department of Urology
`
`Head
`
`Section of Urodynamics and Neuro-urology
`
`Director
`UAMS Incontinence Center
`
`Vice Chief
`
`Section of Pediatric Urology
`
`Medical Director of Urology Clinic
`University of Arkansas for Medical Sciences
`
`Director
`
`Urology Spina Bifida Clinic
`Arkansas Children’s Hospital
`
`OTHER PROFESSIONAL APPOINTMENTS AND INSTITUTIONAL SERVICE:
`
`Hospital Affiliations:
`
`2006- present
`
`Moses Cone Health System
`Greensboro, NC
`
`Patent Owner, UCB Pharma GmbH — Exhibit 2060 - 0003
`
`

`
`MacDiarmid, Scott A., M.D.
`Curriculum Vitae
`
`Page 4 of 50
`
`2003-2006
`
`Attending Urologist
`North Carolina Baptist Hospitals, lnc.
`Winston-Salem, North Carolina
`
`Editorial Work:
`
`May 199'/'—Present
`
`Reviewer
`Journal of Urology
`
`October, 1999-Present
`
`Reviewer
`
`Urology
`
`March, 2000-Present
`
`Reviewer
`
`World Journal of Urology
`
`May, 2003-Present
`
`Reviewer
`International Urogynecology Journal
`
`January 2003 — Present
`
`Reviewer: The Female Patient
`
`May 2003 — Present
`
`Editorial Board Member: The Female Patient
`
`February 2005- Present
`
`Reviewer: Drugs
`
`May 2005 —Present
`
`Reviewer: TheScienticWorld
`
`September 2004 - Present
`
`Reviewer: Neurourology and Urodynamics
`
`September 2007- Present
`
`Reviewer: International Journal of Clinical Practice
`
`Advisogg Board:
`
`1996
`
`1998
`
`Committees:
`
`1996
`
`1996
`
`1997
`
`Surgical Services Board
`University of Arkansas for Medical Sciences
`
`Advisory Board
`Women’s Health Care Center
`
`University of Arkansas for Medical Sciences
`
`Revitalization Committee for the Ambulatory Care Center
`University of Arkansas for Medical Sciences
`
`Practice Development Committee
`University of Arkansas for Medical Sciences
`
`Nominating Committee for the Group Practice Executive Committee
`University of Arkansas for Medical Sciences
`
`Patent Owner, UCB Pharma GmbH — Exhibit 2060 - 0004
`
`

`
`MacDiarmid, Scott A., M.D.
`Curriculum Vitae
`
`Page 5 of 50
`Advisory Committee for the Arkansas Foundation for Urologic
`Disease “ARFUD"
`Board of Directors
`
`Search Committee for replacement for Associate Dean for
`Administration
`
`Obstetrics/Gynecology Chair Search Committee
`University of Arkansas for Medical Sciences
`
`Germantown Medical Executive Committee
`
`CPOE Committee for Surgery
`
`Board of Trustees, Urologic Health Foundation (UHF)
`
`1998
`
`1998
`
`2003
`
`2005
`
`2008
`
`2009-Present
`
`Surgical Services Committee, Cone Health
`
`PROFESSIONAL MEMBERSHIPS:
`
`American Urological Association
`North Carolina Urological Association
`Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction
`South Eastern Section of the American Urological Association — Active Member
`North Carolina Medical Society
`Sigma Phi Chi Medical Fraternity
`American Medical Association
`
`HONORS AND AWARDS:
`
`1978
`
`1978
`
`1991
`
`1995
`
`1997
`
`1998
`
`Highest Academic Achievement Award: Math, Science, and English
`Moncton High School
`New Brunswick, Canada
`
`Governor General‘s Medal for Highest Academic Achievement
`Moncton High School
`New Brunswick Canada
`
`Recognized by Dalhousie University for “Playing a Significant Role in
`the Teaching of Medical Students"
`
`Recognized by University of Arkansas for Medical Sciences for
`“Dedication And Support of UAMS Continuing Medical Education
`Outreach P1'og1°am"
`
`Red Sash Award — awarded by senior class of 1997 at University of
`Arkansas College of Medicine
`
`Best Doctors in Arkansas
`
`Urinary Incontinence
`
`Patent Owner, UCB Pharma GmbH — Exhibit 2060 - 0005
`
`

`
`1998
`
`1998
`
`1999
`
`2001
`
`MacDiarmid, Scott A., M.D.
`Curriculum Vitae
`
`Page 6 of 50
`Best Poster: Treatment of'Post Radical Prostatectomy Bladder Neck
`Contractures With a New Transarethral Balloon Dilatation Catheter.
`16"‘ World Congress of Endourology and SWL
`New York, New York
`
`Essay Finalist: Treatment ofPost Radical Prostatectomy Bladder Neck
`Contractures With a New Transurethral Balloon Dilatation Catheter.
`
`South Central Section Meeting
`American Urological Association
`Cancun, Mexico
`
`Best Doctors in America
`
`Life Member of the National Registry of Who’s Who published in 2001
`edition #164608
`
`2001-2002
`
`America‘s Registry of Outstanding Professionals
`
`2002
`
`2002
`
`2005
`
`Service Chief, Methodist Hospital
`
`Memphis Best Doctors, MD News, July
`
`Highlight Abstract for Publication Neurourology and Urodynamics
`Urinary Incontinence and Incident Disability in Community
`Dwelling Older Women
`Joint Annual Meeting of the Society for Urodynamics and Female
`Urology and the International Society of Pelvic
`Neuromodulation
`
`Orlando, Florida
`
`2005
`
`Blue Ribbon Prize Winner
`
`Flexible Dosing ofExtended—Release Oxybutynin Improves Treatment
`Outcomesfor Urge Incontinence
`The 53rd Annual Clinical Meeting of the American College of
`Obstetricians and Gynecologists.
`San Francisco
`
`Medscape Editor’s Top Picks
`Featured Specialty: Urology
`Lower Urinary Tract Symptoms in Men: A Shifting Paradigm
`Video Panel Discussion: Moderator— SA MacDiarmid
`
`Medscape Urology
`
`Fellowship Award for Medical Student Research Training Program
`Supported by the NIH Short Term Research Training of Medical Students
`grant award
`
`2006
`
`2006
`
`2010-15
`
`Best.Doctors in America Nomination.
`
`2009-2015
`
`Best Doctors in NC Nomination
`
`Patent Owner, UCB Pharma GmbH — Exhibit 2060 - 0006
`
`

`
`MacDiarmid, Scott A., M.D.
`Curriculum Vitae
`
`Page 7 of 50
`
`Major Development Awards
`
`Program Development Award from UAMS in support of UAMS Incontinence Center (1985):
`$400,000.00.
`
`Program Development Award from Chancellor in support of UAMS Incontinence Center
`(1997-1998): $1,400,000.00.
`
`Program Development Award from Don Reynolds Center on Aging in support of satellite
`UAMS Incontinence Center (1999): $240,000.00.
`
`SCHOLARSHIPS:
`
`1982
`1981
`1980
`1979
`
`Academic Entrance Scholarship Medical School
`Academic Scholarship B. SC.
`Academic Scholarship B. SC.
`Academic Scholarship B. SC.
`
`VISITING PROFESSORSI-IIPS/GUEST LECTURES!-IIPS/MODERATOR:
`
`1.
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`9.
`
`Guest lecturer, Charleston Urologic Society, Charleston, North Carolina, November,
`1994.
`
`Clinical preceptor, The Artificial Urinary Sphincter: Technical Aspects and
`Troubleshooting, American Medical Systems, May, 1995.
`
`Visiting Professor, Department of Urology, Louisiana State University School of
`Medicine, Shreveport, Louisiana, January, 1996.
`
`Moderator, Urethral Reconstruction, South Central Section, American Urological
`Association, Vail, Colorado, September, 1996.
`
`Clinical Preccptor, The Artificial Urinary Sphincter: Technical Aspects and Marketing,
`American Medical Systems, April, 1996.
`
`Moderator, Incontinence Symposium: The Artificial Urinary Sphincter, Duke University,
`Durham, North Carolina, August, 1997.
`
`Moderator, Bladder Dysfunction, South Central Section, American Urological
`Association, Cancun, Mexico, November, 1998.
`
`Consultant in Round Table Discussions, Current & Future Trends in Urinary
`Incontinence, American Medical Systems, April, 1998.
`
`Consultant in Round Table Preparation of Nationwide CME Program: Men '5 Health
`Issues, Pfizer, June, 1998; August, 1998.
`
`10. Visiting Professor, Canadian Urological Association Meeting, Topic: Post—Pro.s‘tatectom_v
`Incontinence, Halifax, Canada, June, 1998.
`
`Patent Owner, UCB Pharma GmbH — Exhibit 2060 - 0007
`
`

`
`MacDiarmid, Scott A., M.D.
`Curriculum Vitae
`
`Page 8 of 50
`ll. Visiting Professor, Canadian Urological Association Meeting, Topic: Management of
`Urge and Mixed StresS/Urge Incontinence, Halifax, Canada, June, 1998.
`
`12. Moderator, Nationwide Tele net (CME): Urgency/Frequency Syndrome and Urge
`Incontinence. Sponsor: University of South Dakota School of Medicine, Sioux Falls,
`South Dakota, August, 1998.
`
`13. Moderator, Incontinence Symposium: The Artificial Urinary Sphincter, San Diego,
`California, October, 1998.
`
`14. Moderator, lncontinence Symposium: The Artificial Urinary Sphincter, Duke University,
`Durham, North Carolina, November, 1998.
`
`15. Consultant, BPH Advisory Board, Phoenix, Arizona, Abbott Pharmaceuticals, February,
`1999.
`
`16. Moderator, Nationwide Teleconference — VA Hospitals (CME): Male Urinary
`Incontinence & Benign Prostatic Hyperplasia. Sponsor: GRECC, Minneapolis,
`Minnesota, March, 1999.
`
`17. Moderator, lncontinence Symposium: The Artificial Urinary Sphincter, Los Angeles,
`California, February, 1999.
`
`18. Moderator, Incontinence Symposium: The Artificial Urinary Sphincter, Duke University,
`Durham, North Carolina, April, 1999.
`
`19. Consultant in Round Table Discussions: Current and Future Trends in Urinary
`Incontinence, American Medical Systems, April, 1999.
`
`20. Keynote Speaker. Balloon Dilatation of Urethral Strictures and Bladder Neck
`Contractures, Urinary Tract Infection Advisory Board, Dallas, Texas, Ortlio-McNeil,
`April, 1999.
`
`21.
`
`Consultant, South Central Section Advisory Board. Medical Management of Urinary
`lneontinence, ALZA Pharmaceuticals, Dallas, May, 1999.
`
`22. Keynote Speaker. Overactive Bladder. South Central Section Advisory Board. Medical
`Management of Urinary Incontinence, ALZA Pharmaceuticals, Dallas, May, 1999.
`
`23. Urology and Symposium Chair, CME Round Table Program: A Primary Provider '3'
`Searchfor an Approach to Bladder Control Problems. Future publication in Veteran‘s
`Health System Journal (VHSJ). Coordinated by American MECCA, Chicago, June 25-26,
`1999.
`
`24. Moderator, Urethra & Testis, South Central Section, American Urological Association,
`Santa Fe, New Mexico, September, 1999.
`
`25. Moderator, Nationwide Tele net (CME): Overactive Bladder for Primary Care Physicians:
`University of South Dakota School of Medicine, Sioux Falls, South Dakota, September,
`1999.
`
`Patent Owner, UCB Pharma GmbH — Exhibit 2060 - 0008
`
`

`
`MacDiarmid, Scott A., M.D.
`Curriculum Vitae
`
`Page 9 of 50
`Moderator, Incontinence Symposium. The Artificial Urinary Sphincter, Duke University,
`Durham, North Carolina, October, 1999.
`
`Moderator, Nationwide Tele net (CME): Overactive Bladder Update for Specialists in
`Urology: University of South Dakota School of Medicine, Sioux Falls, South Dakota,
`November 1999.
`
`Advisor, Abbott Pl1armaeeuticals- “Brainstorming Clinical Pharmacology Studies, ABT-
`980 for BPH,” February, 2000.
`
`Advisor, Abbott Pharmaceuticals—“De\/elopment of Symptom Questionnaire for
`Incontinence,” February, 2000.
`
`National Advisory Board Member, Ortho—McNeil Pharmaceuticals, February, 2000-
`present.
`
`Moderator, Statewide Tele-Conference- “BPH for Primary Care Physicians,” Arkansas,
`March, 2000.
`
`Moderator, Statewide Tele—Conference—"Overactive Bladder," Arkansas, March, 2000.
`
`Moderator, Nationwide Tele—Conferencc—“A Practical Approach to Patient with BPH”,
`April, 2000.
`
`Moderator, Nationwide Telc—Conferences, “Overactive Bladder," ALZA Phannaceuticals,
`May-July, 2000.
`
`Moderator, Incontinence Symposium. The Artificial Urinary Sphincter, Duke University,
`Durham, NC, July, 2000.
`
`Moderator, Incontinence Symposium. The Artificial Urinary Sphincter. Duke University,
`Durham, NC, August, 2000.
`
`Keynote Guest Lecturer. Bladder Research Day. A Research Symposium. Dalhousie
`University, Halifax, Nova Scotia, Canada, October, 2000.
`
`Moderator, Incontinence Symposium. The Artificial Urinary Sphincter. Duke University,
`Durham, NC, March, 2001.
`
`Keynote Guest Lecturer. Educating the Primary Care Physician in the Treatment of
`Overactive Bladder. ALZA Phannaceuticals National Training Meeting. Pasadena, CA,
`April, 2001.
`
`Moderator, Incontinence Symposium. The Artificial Urinary Sphincter. Duke University,
`Durham, NC, May, 2001.
`
`Keynote Guest Lecturer. New Innovations in the Management of Overactive Bladder.
`SUNA Meeting. American Urologic Association, Anaheim, CA, .lune, 2001.
`
`Keynote Guest Lecturer. Medical Management of Overactive Bladder. American
`Academy of Nurse Practitioners Annual Meeting, Orlando, FL, June, 2001.
`
`26.
`
`27'.
`
`28.
`
`29.
`
`30.
`
`3].
`
`32.
`
`33.
`
`34.
`
`35.
`
`36.
`
`37'.
`
`38.
`
`39.
`
`40.
`
`41.
`
`42.
`
`Patent Owner, UCB Pharma GmbH — Exhibit 2060 - 0009
`
`

`
`MacDiarmid, Scott A., M.D.
`Curriculum Vitae
`
`Page 10 of 50
`Keynote Guest Lecturer. Educating the Primary Care Physician in the Treatment of
`Overactive Bladder. ALZA Pharmaceutical National Training Meeting, Boston, MA,
`July, 2001.
`
`Innovations in the Medical Management of Overactive Bladder.
`Keynote Guest Lecturer.
`ALZA Pharmaceuticals National Training Meeting, New York, NY, July, 2001.
`
`Moderator, Nationwide Tele-Conference, “Overactive Bladder,” ALZA Phannaceuticals,
`
`July—November, 2001.
`
`Guest Speaker and Moderator. Educating the Primary Care Physician in the Treatment of
`Overactive Bladder. ALZA Pharmaceuticals National Training Meeting, Boston, MA,
`July, 2001.
`
`Medical Advisory Board Meeting, Ortho—McNeil Pharmaceuticals, Ditropan XL.
`Nantucket, MA, August, 2001.
`
`Faculty Reviewer, Duloxetine Primer: Overview of Stress Urinary Incontinence (SUI), the
`SUI Market, and the Duloxetine Compound, Eli Lilly’s SUI Training Program. Eli Lilly
`Phannaceuticals, August, 2001.
`
`Guest Speaker, Incontinence Symposium: Maximizing Treatment of Overactive Bladder.
`Southeastern Region. Atlanta. GA, March, 2002.
`
`Moderator, Regional Speal<er’s Training Meeting, Voiding Dysfunction and Pelvic Pain.
`Ortho-McNeil Phari-naceuticals. Phoenix, AZ, March, 2002.
`
`Medical Advisory Board Meeting, Watson Pharma, Inc. Oxytrol. Atlanta, GA, April,
`2002.
`
`Moderator, Nationwide Tele-Conference, “Overactive Bladder,” Ortho-McNeil
`Pharmaceuticals, April—September, 2002.
`
`Consultant Urologist. Professional Desk—side Briefings (Family Circle, Fitness, Self,
`Health,
`Vogue, Glamour, Town & Country, Parenting, Parents, Cosmopolitan). New York City,
`NY, April, 2002.
`
`Keynote Speaker, Maximizing Treatment of Overactive Bladder. SUNA Meeting.
`American Urological Association. Orlando, FL, May, 2002.
`
`Moderator, Incontinence Symposium. The Artificial Urinary Sphincter. Duke University
`Medical Center. Durham, NC, May, 2002.
`
`Guest Speaker, Overactive Bladder: Current Challenges—Future Solutions. Watson
`Pharma, Inc. Meeting. Boston, MA, June, 2002.
`
`Guest Speaker and Moderator, Overactive Bladder: Key Issues and Treatment Options.
`Watson Pharma, Inc. Rosemont, IL, June, 2002.
`
`Moderator/Speaker Trainer, Urinary Incontinence Symposium. Atlanta, GA, July, 2002.
`Ortho—McNeil Pharmaceuticals.
`
`43.
`
`44.
`
`45.
`
`46.
`
`47.
`
`48.
`
`49.
`
`50.
`
`51.
`
`52.
`
`53.
`
`54.
`
`55.
`
`56.
`
`57.
`
`58.
`
`Patent Owner, UCB Pharma GmbH — Exhibit 2060 - 0010
`
`

`
`MacDiarmid, Scott A., M.D.
`Curriculum Vitae
`
`Page ll of 50
`
`59. Guest Lecturer, Women with Bladder Dysfunction: The Art of Patient Management.
`Baylor College of Medicine. Orlando, FL, July, 2002.
`
`60. Guest Speaker, The Role of the Primary Care Physician in the Treatment of Overactive
`Bladder. Denver, CO, July, 2002. Ortho—McNeil Pharmaceuticals.
`
`61. Guest Speaker, Establishment of a Continence Center. Denver, CO, July, 2002. Ortho-
`McNeil Pharmaceuticals.
`
`62. Moderator, Central/North Central Region Consultant Meeting. Toronto, Canada, August,
`2002.
`
`63.
`
`Strategic Task Force Member, Bladder Matters Health Initiative. August, 2002. Ortho-
`McNeil Pharmaceuticals.
`
`64. Guest Speaker, The Role of Pharmacokinetics in the Treatment of Overactive Bladder.
`Pri—med Symposium. Chicago, IL, September, 2002. Watson Urology.
`
`65. Moderator, Nationwide Teleconference, “Overactive Bladder.” Ortho—McNeil
`Pharmaceuticals, September-November, 2002.
`
`66.
`
`Steering Committee Member. Bladder Matters Health Initiative. Ortho—McNeil
`Pharmaceuticals November, 2002.
`
`67. Guest Physician. The Role of Botox in the Treatment of Urinary Incontinence. Methodist
`Le Bonheur Healthcast, Memphis, TN, November, 2002.
`
`68.
`
`Faculty Speaker. Bladder Health Nurse Advisory Board. Philadelphia, PA, November
`2002.
`
`69. Oxytrol Scientific Advisory Board Member. Palm Beach, FL. January, 2003. Watson
`Urology.
`
`70. Moderator, Nationwide Teleconference, “Bladder Matters Speaker Training,” April, 2003.
`Ortho—McNeil Pharmaceuticals.
`
`71. National Advisory Board Member Meeting. The Role of Tropsium Hydrochloride in the
`Treatment of Overactive Bladder. Miami, FL, November, 2002. lndevus Phannaceuticals.
`
`72. Guest Lecturer. Management Strategies for the Overactive Bladder. Society of Urologic
`Nurses and Associates (SUNA) 34”‘ Annual Meeting. San Antonio, TX, April, 2002.
`
`73. Moderator, Nationwide Teleconference, “Bladder Matters: Clinical Insights on Urologic
`Health,” April-May, 2003. Ortho—McNeil Pharmaceuticals.
`
`74.
`
`Steering Committee Member. The Public Health Implications of Urogenital Disease: A
`Focus on Overactive Bladder. Washington, DC, January, 2003.
`
`75. Moderator. Bladder Matters: Clinical Insights on Urologic Health Meeting. Hollywood,
`CA, January, 2003. Ortho—McNeil Pharmaceuticals.
`
`Patent Owner, UCB Pharma GmbH — Exhibit 2060 - 0011
`
`

`
`Page 12 of 50
`Advisory Board Member. Bladder Matters: Clinical Insights on Urologic Health
`Consultant Board Meeting. San Francisco, CA, March, 2003. Ortho—McNeil
`Pharmaceuticals.
`
`MacDiarmid, Scott A., M.D.
`Curriculum Vitae
`
`National Advisory Board Member Meeting. Darifenacin as a Treatment of Overactive
`Bladder, April, 2003. Novartis
`
`Faculty/Guest Speaker Canadian National Advisory Board Meeting. Ditropan XL.
`Kingston, Jamaica. May. 2003
`
`Consultant. Treatment of Overactive Bladder in Special Patient Populations. Montreal,
`Canada. August, 2003. Med Reviews, LLC.
`
`Advisory Board Member. OAB Advisory Meeting. Charleston, SC. August, 2003. Mc-
`Neil Consumers & Specialty Pharmaceuticals.
`
`Moderator. Elmiron Regional Advisory Board Meeting. October, 2003. Cincinnati, OH.
`Ortho—McNeil Pharmaceuticals.
`
`Moderator. Nationwide Teleconference. Oxytrol: Scientific Data, Clinical Experience,
`and Practical Solutions. September, 2003 — November, 2003. Watson Pharma, Inc.
`
`Guest Lecturer. Treatment Options for OAB. Women’s Health Consultants’ Forum.
`December, 2003. Phoenix, Arizona. Watson Pharma, Inc.
`
`Advisory Board Member. Ditropan XL National Advisory Board Meeting. December,
`2003. Chicago, Illinois.
`
`Guest Interview. Urinary Incontinence. Winston—Salem, NC. December, 2003.
`
`Guest Interview. Urinary Incontinence. Winston-Salem, NC. December, 2003. CBS
`Affiliate.
`
`Faculty. Regional Leadership Series. Overactive Bladder. February, 2004. Key
`Biscayne, Florida. Pfizer, Inc.
`
`Moderator, New Perspectives on Chronic Pelvic Pain Syndrome. Atlanta. March, 2004.
`Ortho—McNeil Pharmaceuticals.
`
`Moderator. Nationwide Teleconference. (CD Rom) “Bladder Matters: New Perspective
`on Pelvic Health Management.” April, 2004. Ortho—McNeil Pharmaceuticals.
`
`Global Advisory Board. Enablex (Darifenicen). Dublin, Ireland. April, 2004.
`Novartis.
`
`Moderator. Nationwide Teleconference. Oxytrol: Treatment of OAB. April, 2004 —
`September, 2004. Watson, Pharma, Inc.
`
`Moderator. Bladder Matters Regional Advisory Board Meeting. Chapel Hill, NC. May,
`2004. Ortho—McNeil Pharmaceuticals.
`
`76.
`
`77.
`
`78.
`
`79.
`
`80.
`
`81.
`
`82.
`
`83.
`
`84.
`
`85.
`
`86.
`
`87.
`
`88.
`
`89.
`
`90.
`
`92.
`
`Patent Owner, UCB Pharma GmbH — Exhibit 2060 - 0012
`
`

`
`MacDiarmid, Scott A., M.D.
`Curriculum Vitae
`
`Page 13 of 50
`93. Advisor. 2004 Bladder Matters Consultant Newsletter Series. Ortho—McNeil
`Pharmaceuticals.
`
`94. Key Note Speaker. “Maximizing the Treatment of Overactive Bladder.” Mid— West
`Geriatrics Symposium: The Aging Bladder. Champagne, Illinois. May, 2004.
`
`95. Moderator. Bladder Matters Regional Advisory Board Meeting. Plymouth, MN. May,
`2004. Ortlio-McNeill Pharmaceuticals,
`
`96. Advisor. Fesoterodine US Roundtable Meeting. San Francisco, CA. May, 2004.
`Schwarz Phanna.
`
`97.
`
`98.
`
`99.
`
`Course Director. New Treatment for the Overactive Bladder. American Urological
`Association Meeting. San Francisco, CA. May, 2004.
`
`Post—Graduate Course Faculty. Advancements and New Frontiers in Incontinence
`and Voiding Dysfunction. American Urological Association Meeting. San Francisco,
`CA. May, 2004.
`
`Faculty. New Strategies for the Treatment of OAB: Vision, Perfonnance and
`Future Directions. "Towards Optimal Pharmacology of OAB Therapy". International
`Consultation on Incontinence, Satellite Symposium, Monaco, June, 2004.
`
`100. Advisor. Oxytrol Regional Consultant Meeting. "Why Transdermal
`Oxybutynin‘?"; How to Educate Physicians on the Oxybutynin Transdennal
`System and Related lssues". Providence, Rhode Island, July 2004.
`
`101. Key Note Speaker. South Carolina Urological Association Annual Meeting. "Mid-
`urethral Slings". Columbia, SC. September, 2004.
`
`102. Faculty. Oxytrol Nationwide Teleconference. Overactive Bladder: New
`Therapeutic Options. September, 2004.
`
`103. Faculty. Overactive Bladder: The Path to Successful Outcomes. A CME Satellite
`Symposium "Maximizing Antieholinergic Therapy for OAB: Has the Ceiling Been
`Reached? The 27th Congress of the Society of International Urologists. Honolulu, Hawaii.
`October, 2004.
`
`104. Key—Note Speaker. Mid—urethral Slings. The 28th Annual Frank R. Lock OB/GYN
`Symposium. Wake Forest University. Winston-Salem. October, 2004.
`
`I05. Faculty. Oxytrol Region al Consultant Meeting. "Efficacy and Safety of Oxytrol".
`Chicago, Illinois, October, 2004.
`
`106. Co—Chairman. Ditropan XL Primary Care Advisory Board. "Management
`Strategies for OAB". Philadelphia, Pennsylvania, October, 2004.
`
`107. Key Note Speaker. Nationwide Canadian Virtual Symposium. "A Clinical Review
`and Evidence-Based Introduction to Oxytrol". Toronto, Canada, November, 2004.
`
`108. Advisor. Odyssey/lndevus National Advisory Board Meeting. Miami, Florida,
`October, 2004.
`
`Patent Owner, UCB Pharma GmbH — Exhibit 2060 - 0013
`
`

`
`MacDiarmid, Scott A., M.D.
`Curriculum Vitae
`
`Page 14 of 50
`
`109.
`
`110.
`
`Ill.
`
`H2.
`
`H3.
`
`ll4.
`
`115.
`
`116.
`
`117.
`
`M8.
`
`119.
`
`120.
`
`121.
`
`122.
`
`Faculty. GlaxoSmithKline Overactive Bladder Webcast Roundtable. November,
`2004.
`
`Advisor. Ditropan OTC Advisory Board Meeting. Philadlephia, Pennsylvania.
`January, 2005.
`
`Faculty. NAFE Nationwide Teleconference. Overactive Bladder. New York, New York.
`January, 2005.
`
`Advisor. Ditropan XL National Advisory Board Meeting. Dallus, Texas. January, 2005.
`
`Visiting Professor. What's New in the Management of OAB? Department of Obstetrics
`and Gynecology. University of Tennessee. Memphis, Tennessee. February, 2005.
`
`Faculty. Watson Pharma Regional Consultant Meeting. "Treating OAB with Oxytrol: A
`Clinical Review". Charleston, South Carolina. March, 2005.
`
`Advisor. Watson Oxytrol Speaker’s Update Meeting. Dallus, TX. Oct, 2005.
`
`Guest speaker. OrthoUrology POA National Mtg Southeastern Region. Atlanta, GA. 2005
`
`Guest speaker. OrthoUrology POA National Meeting Westem Regions. Dallus, TX. 2005.
`
`Advisor. Ditropan XL Advisory Board Meeting. Miami, FL. Jan, 2006.
`
`Advisor. Astcllans Urology Advisory Board. Miami, FL, Jan, 2006.
`
`Faculty. Raising the Bar in the Management of OAB. Pittsburg, PA. March, 2006. (CME)
`
`Faculty. Watson Pharma Regional Consultant Meeting. "Treating OAB with Oxytrol: A
`Clinical Review". Charleston, South Carolina. April, 2005.
`
`Faculty. Detrol LA Regional Advisory Board Meeting. "The Role of Anticholinergics in
`Men with Lower Urinary Tract Symptoms". Miami, Florida. May, 2005.
`
`123. Lecturer. Maximizing the Treatment of OAB. Department of Geriatrics. Wake Forest
`University. July, 2005.
`
`124. Advisor. Fcsoterodinc Roundtablc Meeting. Chicago. IL. July, 2005.
`
`125. Speaker. Management of Overactive Bladder. First Annual Women’s Health
`Symposium. Winston-Salem. Sept, 2005.
`
`126. Faculty. Watson Phanna Regional Consultant Meeting. Charleston, SC. Sept, 2005.
`
`127. Faculty. Medical Management of OAB. Kentucky Urologic Association Annual
`Meeting. Sept, 2005.
`
`Patent Owner, UCB Pharma GmbH — Exhibit 2060 - 0014
`
`

`
`MacDiarmid, Scott A., M.D.
`Curriculum Vitae
`
`Page 15 of 50
`128. Faculty. Treatment of OAB: What do Patients Want and What Do Physicians Provide?
`35"‘ Annual Meeting of the International Continence Society. Montreal, Canada. Sept,
`2005.
`
`129. Presenter. What We Know About Flexible Dosing in the Treatment of OAB. 35"’
`Annual Meeting of the International Continence Society. Montreal, Canada. Sept,
`2005.
`
`130. Faculty. Male OAB Advisory Board. Dallus, TX. Oct, 2005.
`
`I31. Faculty. Male OAB Advisory Board. Atlanta, GA. Oct, 2005.
`
`132. Faculty. Clinical Effectiveness of OAB Management — Patient and Physician
`Perspectives. Medical Crossfire. North Eastern Section AUA. New York, NY. Oct,
`2005.
`
`133. Faculty. Clinical Effectiveness of OAB Management — Patient and Physician
`Perspectives. Medical Crossfire. South Central Section AUA. Southhamptom,
`Bermuda. Nov, 2005.
`
`134. Presenter. Rethinking the Treatment of Men with Lower Urinary Tract Symptoms.
`Teleconference Series. Jan, 2006.
`
`135. Faculty. Countdown to Continence Development Meeting. Miami, Florida. Feb, 2006.
`
`136. Faculty. Male OAB Advisory Board. Miami, Florida. Feb, 2006.
`
`I37. Faculty. Overactive Bladder: Debating the Controversies in Therapeutic Management.
`Veritas Institute CME. Bond’s Cay. Feb, 2006.
`
`138. Presenter. Ditropan XL 2006 Promotional Speaker Training Web Conference. Feb,
`2006.
`
`139. Visiting Professor. Non-Surgical Treatment of Urethral Stricture Disease. McKay
`Department of Urology. Carolinas Medical Center. March, 2006.
`
`I40. Visiting Professor. Overactive Bladder: Maximizing Outcomes and New Areas of
`Research. Department of Urology. Royal Victoria Hospital, Montreal, Canada. March,
`2006.
`
`14]. Faculty. Innovative Speaker Training Program— OAB in Men. Ann Arbor. Michigan.
`March, 2006.
`
`142. Presenter. OAB-WRAP- A Leading Investigator, First Person Clinical Report.
`http://clinicalwebcastscom (CME), 2006.
`
`143. Speaker. Role of Antimuscarinics in the Management of Male LUTS. Washington
`Urological Associated Meeting. Washington, DC. Nov, 2006.
`
`144. Visiting Professor. The role of anticholinergics and urodynamics in male LUTS.
`Department of Urology. Laval University. Quebec, Canada. Oct, 2006.
`
`Patent Owner, UCB Pharma GmbH — Exhibit 2060 - 0015
`
`

`
`MacDiarmid, Scott A., M.D.
`Curriculum Vitae
`
`Page 16 of 50
`
`145. Visiting Professor. Maximizing the treatment of OAB. Department of Obstetrics and
`Gynecology. Laval University. Quebec, Canada. Oct, 2006.
`
`146. Faculty. Enablex Continence Education Faculty Meeting. San Diego, CA. Jan, 2007.
`
`I47. Faculty. Enablex Train—The—Trainer Meeting. Coral Gables, FL. Jan, 2007.
`
`I48. Adviser. Global Advisory Council for Urology Indications. Clinical Liaison Group.
`Jan, 2007.
`
`149. Advisor. MdConversation Advisory Meeting. Alberta, Canada. Jan, 2007.
`
`150. Presenter. Emerging role of botulinum toxin in urology. MdConversation Advisory
`Board. Alberta, Canada. Jan, 2007.
`
`151. Visiting Lecturer. Treating the Male Overactive Bladder Patient. Tampa Bay Urologic
`Society. Feb, 2007.
`
`152. Faculty. Innovative Speaker Training on Overactive Bladder in Men. Groton,
`Connecticut. Feb, 2006.
`
`153. Advisor. Esprit Leadershiop GUILD Advisory Board. Sunny Isles, FL. Feb, 2006.
`
`154. Faculty. Overactive Bladder: Debating the Controversies in Therapeutic Management.
`Society for Urodynamics and Female Urology Winter Meeting. Bahamas. Feb, 2006.
`
`155. Faculty. An Update on Pharmacological Treatments for OAB and Surgical Treatments
`for Incontinence and Pelvic Floor Prolapse. Department of Urology. Toronto, Canada.
`March, 2006.
`
`156. Faculty. Challenges in Managing Urge Incontinence/OAB in the Elderly Patient:
`Evaluating Safety, Efficacy, and Side Effect Issues for Drug Therapy—Applying
`landmark Trials to Clinical Practice. April, Miami, Florida. (CME)
`
`I57. Consultant. Expert Meeting— ‘(M178 Urodynamic Study in Male LUTS Patients.
`Astellas Pharma. May, 2006.
`
`158. Faculty. Countdown to Continence: The Pursuit of Dryness and Improved Quality of
`Life. CME Teleconference Series. 2006.
`
`159. Faculty. Spotlight on Overactive Bladder—Integrating Trials into Clinical Practice.
`AUA Annual Meeting, Atlanta, GA. May, 06.
`
`160. Moderator. Ditropan XL Flexible Dosing Rep Training module. June, 2006.
`
`I61. Faculty Speaker. CME Overactive Bladder Medical Center Briefing. Naval Medial
`Center, Portsmouth, VA. June, 2006.
`
`162. Moderator. Ditropan XL Flexible Dosing Teleconferences. July—Dec, 2006.
`
`Patent Owner, UCB Pharma GmbH — Exhibit 2060 - 0016
`
`

`
`MacDiarmid, Scott A., M.D.
`Curriculum Vitae
`
`Page 17 of 50
`163. Presenter. An Update for Managed Care Pharrnacologic Management of Overactive
`Bladder- Teleconference Series. (CME) July, 2006.
`
`164. Faculty Speaker. CME Overactive Bladder Medical Center Briefing. University of
`Kentucky Medical Center. Lexington, KY. Aug, 2006.
`
`165. Advisor. Fesoterodine Working Group Meeting. Chicago, IL. August, 2006.
`
`166. Advisor. Esprit Leadership Guild Advisory Board. Chicago, IL. August, 2006.
`
`167. Speaker. A Clinical Update of Oxytrol and Transdermal Science. Oxytrol National
`Urology Consultants Meeting, Boston, MA. 2006.
`
`168. Advisor. Oxytrol National Urology Consultants Meeting. Boston, MA. September,
`2006.
`
`169. Visiting Professor. Atlantic Canada Urology Update. Overactive Bladder-Current
`Concepts. Prince Edward Island, Canada. Sept, 2006.
`
`170. Visiting Professor. Atlantic Canada Urology Update. Botulinum Toxin and the
`Overactive Bladder. Prince Edward Island, Canada. Sept 2006.
`
`171. Presenter. Insights into the Pathophysiology and Therapeutic Managementy of
`Overactive Bladder. Georgetown University Hospital. Sept, 2006.
`
`172. Consultant. Male Nexus OAB Consultant Meeting-Pfizer. Oct, 2006.
`
`173. Moderator. Detrol LA Meet the Experts. Raleigh, NC. Nov, 2006.
`
`174. Faculty. Urologic Health Foundation (UHF) National Steering Committee Meeting.
`Las Vegas, Nevada. Nov, 2006.
`
`175. Presenter. Evaluating and treating male LUTS in primary care setting: an interactive
`case. Medscape, Nov, 2006. http://www.medscape.comiviewgrogram/6287.
`
`176. Faculty. Everything you need to know for OAB. Pri—Med. Orlando, FL. Oct, 2006.
`
`177. Speaker. Improving the Management of Urinary Incontinence in the Older Adult:
`Evaluation the Clinical Literature. Kansas City, MS. Nov, 2007.
`
`178. Presenter. Titration Investigation: Flexible Dosing in Overactive Bladder. Online
`Journal Club. Oct, 2007.
`
`179. Faculty. Everything you need to know for OAB. Pri—Med. Washington, DC. Nov,
`2006.
`
`180. Faculty. The Urge to Define Urgency. Anaheim, CA. May, 2007.
`
`181. Moderator. CLOVER Regional Advisory Board. Greensboro, NC. June, 2007.
`
`182. Faculty. Sanctura Case Study Development Meeting. June, 2007.
`
`Patent Owner, UCB Pharma GmbH — Exhibit 2060 - 0017
`
`

`
`MacDiarrnid, Scott A.,